bullish

Ipca Laboratories (IPCA IN): Domestic Revenue Drives Q1FY25 Result; Full-Year Margin Guidance Raise

558 Views07 Sep 2024 17:23
​Ipca Laboratories reported 12% domestic revenue growth in Q1FY25, with higher EBITDA margin. The company reduced FY25 revenue growth guidance to ~9% and raised EBITDA margin guidance to 18.5–19.0%.
What is covered in the Full Insight:
  • Introduction
  • Financial Performance
  • Challenges and Setbacks
  • Strategic Initiatives and Innovations
  • Share Performance and Valuation
Boomeranged on Sun, 3 Nov 2024 22:29
Ipca will announce Q2FY25 result on November 14. Thus far, Indian pharma companies have reported strong domestic revenue. We are expecting similar performance from Ipca. Accumulate before the result announcement.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x